*Read Disclaimer Sponsored Content | Unsubscribe
Hello!
New Alert: Medicus Pharma Ltd. (NASDAQ: MDCX)
MDCX is our brand new NASDAQ alert.
The company has a chart setup positioning for a potential breakout higher.
Moreover, it has a history of large moves in a short period of time.
In May, the company traded as high as almost 9.00…
That's 200% from here.
But it doesn't have to go up that high to experience double- or triple-digit gains.
MDCX has a 50 day moving average of 4.05, 37% above yesterday's close.
Large gaps like this often create big opportunities.
Now might be no different.
The momentum may already be in place.
With a chart setup pointing to a breakout opportunity.
In addition, on Monday the company announced pretty important news.
MDCX is a NASDAQ listed "biotech/life sciences company".
MDCX is "focused on accelerating the clinical development programs of novel and disruptive therapeutics assets".
MDCX is "actively engaged in multiple countries, spread over three continents".
"SkinJect Inc., a wholly owned subsidiary" of MDCX, is "focused on commercializing novel, non-invasive treatment for basal cell skin cancer".
It's "using patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumors cells".
As the company further explains:
- "SKNJCT-003 Phase 2 clinical study is currently underway in nine (9) clinical sites across United States which commenced randomizing patients in August 2024."
- "In March 2025, the Company also announced a positively trending interim analysis for SKNJCT-003 demonstrating more the 60% clinical clearance."
- "The interim analysis was conducted after more than 50% of the then-targeted 60 patients in the study were randomized."
MDCX has announced multiple accomplishments recently.
In May, the company announced:
- "Medicus Pharma Ltd Receives Study May Proceed Approval from United Arab Emirates (UAE) Department of Health (DOH) to Commence Phase 2 Clinical Study (SKNJCT-004) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)"
Earlier in June, the company announced:
"Medicus Pharma Ltd. Announces Submission of Product Development Plan to the Food and Drug Administration (FDA) to Treat External Squamous Cell Carcinoma (SCC) in Horses"
- "Company Is Advancing Use of Novel Doxorubicin-containing Microneedle Array (D-MNA) Patch in Veterinary Oncology as an Orphan Drug"
Importantly:
"The Company, in December 2024, received a Minor Use in Major Species Designation (MUMS) for its dissolvable Doxorubin-containing microneedle array (D-MNA) to treat external squamous cell carcinoma (SCC) in horses. The product development plan is designed to seek concurrence of the FDA under MUMS designation."
"MUMS is a status similar to Orphan Drug status for human drugs. It entitles the Company to an extended 7-year period of exclusive marketing following approval or conditional approval, provided that the Company meets all requirements for maintaining the designation."
On Monday, the company announced breaking news:
"Medicus Pharma Ltd Announces a Definitive Agreement to Acquire Antev Ltd. UK"
- "Antev Shareholders to Receive Aggregate ~17% Equity Stake in Medicus plus US$65 Million in Contingent Payments"
As the company further explains:
"Antev is a clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as first in market product for cardiovascular high-risk prostate cancer patients and patients with first acute urinary retention (AURr) episodes due to enlarged prostate."
Importantly:
"Teverelix is aiming to be the first-in-class indication product for preventing recurrence of acute urinary retention (AURr) in males 45 years or older, who suffer from prostate enlargement."
In addition:
"Antev has a US Food and Drug Administration (FDA) approved phase 2b study designed to randomize 390 men after a successful trial without catheterization (TWOC)."
Also, "Teverelix is aiming to be the best-in-class indication product for hormone therapy for advanced prostate cancer (APC) patients with increased CV risk".
Sadly, "300,000 to 500,000 men in the US are living with advanced stage prostate cancer".
If approved, "Teverelix could become the first hormone therapy labeled specifically for treating prostate cancer in patients with a history of cardiovascular disease".
MDCX could be positioned for increased growth potential.
Make sure to do your own due diligence.
Sources: PR1, PR2, PR3, PR4, PR5, PR6, PR7, Website, Chart
Happy Trading!
SmallCapStocks Team
Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose.
Tidak ada komentar:
Posting Komentar